|
Richard Murray, Ph.D. has served as PDL BioPharma�s Vice President, Research since April 2003 and was recently made Senior Vice President, Chief Scientific and Technical Officer. Prior to PDL BioPharma, Dr. Murray co-founded Eos Biotechnology, Inc., where he served as Vice President, Research at Eos from February 1998 to April 2003 before joining PDL BioPharma�s management team through the company�s acquisition of Eos. Dr. Murray was responsible for the discovery and transition of antibody-based therapeutic candidates from research to development. Prior to Eos, Dr. Murray was a staff scientist, then senior staff scientist at DNAX Research Institute, where he established the transgenic and knock-out mouse program. Dr. Murray received a Ph.D. from the University of North Carolina in Chapel Hill with his work in the area of immuno-genetics.
| 